For the Inventor, By the Inventor

Enter assignee name

New York, NY, United States of America

Ovid Therapeutics Inc.

USPTO Granted Patents = 51

% Expired Patents = 3.9

EPO Patents = 6

Trademarks = 4

Forward Citations = 220

Loading Chart...

Loading Chart...

3 inventors (with patents filed for the assignee):

Matthew J During (51 out of 68 patents)

Anna Kazanchyan (3 out of 7 patents)

Brett Abrahams (3 out of 3 patents)

Core Competencies:

Gaboxadol

Developmental Disorders

Seizure Disorders

Epileptic Disorders

PDE10A Inhibitors

MIR101

MIR128

Tourette Syndrome

Prader-Willi Syndrome

Biguanides

Tinnitus

Behavioral Syndromes

51 patents: Sort by Forward Citations

1. 12465597 - Methods of treating developmental disorders with gaboxadol (2025-11-11),

2. 12285397 - Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders (2025-04-29),

3. 12144801 - Methods and compositions for treatment of epileptic disorders (2024-11-19),

4. 12109201 - Methods and compositions for treatment of epileptic disorders (2024-10-08),

5. 11918563 - Methods and compositions for treatment of epileptic disorders (2024-03-05),

6. 11918551 - Methods of treating seizure disorders and Prader-Willi syndrome (2024-03-05),

7. 11903930 - Methods and compositions for treatment of epileptic disorders (2024-02-20),

8. 11806336 - Methods and compositions for treatment of epileptic disorders (2023-11-07),

9. 11771671 - Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction (2023-10-03),

10. 11761006 - Use of MIR101 or MIR128 in the treatment of seizure disorders (2023-09-19),

11. 11690829 - Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder (2023-07-04),

12. 11660277 - Use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders (2023-05-30),

13. 11395817 - Methods and compositions for treatment of epileptic disorders (2022-07-26),

14. 11364228 - Gaboxadol for therapeutic treatment of 1p36 deletion syndrome (2022-06-21),

15. 11291658 - Use of gaboxadol in the treatment of diabetes and related conditions (2022-04-05),

Company Overview

Ovid Therapeutics Inc. is a biopharmaceutical company based in New York, specializing in the development of innovative therapies for patients with developmental and seizure disorders. The company focuses on advancing treatments for conditions such as Tourette Syndrome and other epileptic disorders, leveraging its expertise in core technologies like Gaboxadol and PDE10A inhibitors. Ovid is committed to addressing unmet medical needs through rigorous research and development in the field of neurology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

51 Patents

#190 in New York, NY

#423 in New York

#6,884 in US

#13,776 in the World

New York, NY, United States of America

Ovid Therapeutics Inc.

Forward Citations = 220

3 inventors:

Matthew J During (51 out of 68 patents)

Anna Kazanchyan (3 out of 7 patents)

Brett Abrahams (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ovid Therapeutics Inc.. Retrieved from https://idiyas.com/company/ovid-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…